Overview of biomarkers in myasthenia gravis
Fatemeh Afrashteh , Rayan Rajabi
Exploration of Neuroprotective Therapy ›› 2022, Vol. 2 ›› Issue (5) : 210 -225.
Myasthenia gravis (MG) is a rare auto-immune neuromuscular junction (NMJ) disorder which is caused by formation of autoantibodies and destruction of NMJ components. The MG diagnosis is based on the symptoms, autoantibodies detection and paraclinical tests. Given that MG patients have so many differential diagnosis and various medication responses, choosing an accurate diagnosis and the therapy plan in MG is challenging. According to the studies, there are the immunologic, genetic, microRNAs, gut microbiome, and other established or newly proposed biomarkers for diagnosis and prognosis of MG. More studies are needed to provide better collection of biomarkers in MG patients and evaluate their role in MG pathology.
Myasthenia gravis / biomarker / autoimmune disease / neuromuscular junction
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord. 2006; 16: 459-67. |
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
Kawakami Y, Ito M, Hirayama M, Sahashi K, Ohkawara B, Masuda A, |
| [15] |
|
| [16] |
Evoli A, Bianchi MR, Riso R, Minicuci GM, Batocchi AP, Servidei S, |
| [17] |
|
| [18] |
|
| [19] |
Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, |
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
Buckley C, Newsom-Davis J, Willcox N, |
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, |
| [32] |
Suzuki S, Satoh T, Yasuoka H, Hamaguchi Y, Tanaka K, Kawakami Y, |
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
Illa I, Cortés-Vicente E, Martíƴnez MÁƵ , Gallardo E. Diagnostic utility of cortactin antibodies in myasthenia gravis. Ann N Y Acad Sci. 2018; 1412: 90-4. |
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
Tu H, Pirskanen-Matell R, Heikkinen A, Oikarainen T, Risteli J, |
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013; 14: e218-28. |
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
|
| [83] |
Frank DN, |
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, |
| [88] |
Nagano Y, Itoh K, |
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
/
| 〈 |
|
〉 |